Any current/future new fundraising through debt or equity?

For FY26, Laurus Labs plans a capex of around INR 1,000 crores, primarily toward CDMO and formulation businesses and fermentation capacity expansion. Management indicated that debt levels will not significantly increase with this capex; debt may fluctuate around ±10%, roughly INR 250 crores. They expect to manage capex largely through internal cash flows without major additional borrowing. No specific plans for equity fundraising were mentioned in the call. The company aims to maintain a stable balance sheet with net debt/EBITDA ratio improving from 3.1 to 2.3. Overall, no significant new debt

Any current/future capex/capital investment/strategic investment?

FY26 capex is planned around INR1,000 crores. Major capex focus areas include: - Increasing formulation CMO capacity. - Specific capex for a formulation partner. - Fermentation capacity expansion in Vizag with close to INR250 crores. - Adding production blocks at Vizag for API and CDMO businesses. No significant increase in debt is expected to support this capex. No new greenfield facilities are expected to start operations in FY26; expansion is mostly through existing sites. INR5,000 crores capex announcement includes backward integration and de-risking the supply chain to reduce depe

Future growth expectations in sales/revenue/volumes?

CDMO segment is expected to grow significantly, driven by ongoing and new projects with big pharma partners, including human health, animal health, and crop sciences divisions. CDMO revenue contribution increase anticipated to improve overall margins. ARV revenues expected to remain stable around INR 2,500-2,600 crores in the medium term; no major growth expected there. Non-ARV formulations sales to rise, especially from approvals in US and Canada and new CMO contracts. Animal health business to see a significant revenue jump by FY26 post commercial validations. Crop sciences busines

Future growth expectations in earnings/operating earnings/profits/EPS?

Laurus Labs expects significant growth in revenues and profitability in FY26 compared to FY25, driven notably by the CDMO and formulation segments. CDMO revenues are projected to grow, with an associated improvement in EBITDA margins as the CDMO share increases. Overall operating margin is expected to improve due to better asset utilization and enhanced product mix. Return on capital employed (ROCE) is anticipated to improve from current near-double digit levels but no specific timeline was provided. Capex of around INR1,000 crore planned for FY26 primarily to expand CDMO/CMO capacities, with

Current/ Expected Orderbook/ Pending Orders?

The active pipeline projects have increased significantly to 110 currently, up from around 60 two to three years ago. Out of the 110, about 90 projects are in human health and 20 in animal health. Majority of these projects are in advanced phases, primarily Phase 2 and Phase 3, indicating strong revenue potential. The number of Requests for Proposal (RFPs) has also seen a significant increase, signaling growing order intake. CDMO projects are long and complex with longer order-to-delivery timelines, contributing to higher working capital and backlog. Animal health CDMO is expected to

IN US

Sale is live|00:00:00left today

Laurus Labs LtdQ1 FY25Pharmaceuticals & Biotechnology

Laurus Labs Ltd Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,450P/E: 80.4Market Cap: ₹71.5K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Order

Yes

Capex

Yes

2 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→CDMO segment is expected to grow significantly, driven by ongoing and new projects with big pharma partners, including human health, animal health, and crop sciences divisions.
→CDMO revenue contribution increase anticipated to improve overall margins.
→ARV revenues expected to remain stable around INR 2,500-2,600 crores in the medium term; no major growth expected there.
→Non-ARV formulations sales to rise, especially from approvals in US and Canada and new CMO contracts.
→Animal health business to see a significant revenue jump by FY26 post commercial validations.
→Crop sciences business is nascent, expected to mature over next year for clearer outlook.
→Capex focused on CDMO/CMO expansions, expected to fuel growth in these segments.
→Working capital increases due to complex CDMO projects and higher formulation sales expected to normalize.
→Overall FY26 outlook anticipates growth in revenues and profitability, with better asset utilization.

Margin guidance

Category 3

→Laurus Labs expects significant growth in revenues and profitability in FY26 compared to FY25, driven notably by the CDMO and formulation segments.
→CDMO revenues are projected to grow, with an associated improvement in EBITDA margins as the CDMO share increases.
→Overall operating margin is expected to improve due to better asset utilization and enhanced product mix.
→Return on capital employed (ROCE) is anticipated to improve from current near-double digit levels but no specific timeline was provided.
→Capex of around INR1,000 crore planned for FY26 primarily to expand CDMO/CMO capacities, with minimal increase in debt.
→The growth outlook includes strong pipeline projects mostly in late stages (phase 2 and 3), supporting sustained revenue growth.
→Management refrains from providing precise numerical financial guidance but is confident on a positive trajectory in earnings and margins over the medium term.

3 more insights locked — sign up free to unlock

Fundraise plans

→For FY26, Laurus Labs plans a capex of around INR 1,000 crores, primarily toward CDMO and formulation businesses and fermentation capacity expansion.
→Management indicated that debt levels will not significantly increase with this capex; debt may fluctuate around ±10%, roughly INR 250 crores.
→They expect to manage capex largely through internal cash flows without major additional borrowing.
→No specific plans for equity fundraising were mentioned in the call.
→The company aims to maintain a stable balance sheet with net debt/EBITDA ratio improving from 3.1 to 2.3.
→Overall, no significant new debt or equity fundraising is projected in the near term.

Order book

Yes

→The active pipeline projects have increased significantly to 110 currently, up from around 60 two to three years ago.
→Out of the 110, about 90 projects are in human health and 20 in animal health.
→Majority of these projects are in advanced phases, primarily Phase 2 and Phase 3, indicating strong revenue potential.
→The number of Requests for Proposal (RFPs) has also seen a significant increase, signaling growing order intake.
→CDMO projects are long and complex with longer order-to-delivery timelines, contributing to higher working capital and backlog.
→Animal health CDMO is expected to see a significant revenue jump starting FY26 as validations complete and commercial production begins.
→Crop sciences CDMO is commercialized recently, with some projects under negotiation and feasibility studies—expected to mature in another year.
→Overall, the orderbook indicates robust growth potential especially in the human health and animal health CDMO segments.

Capex plans

Yes

→FY26 capex is planned around INR1,000 crores.
→Major capex focus areas include:
→ - Increasing formulation CMO capacity.
→ - Specific capex for a formulation partner.
→ - Fermentation capacity expansion in Vizag with close to INR250 crores.
→ - Adding production blocks at Vizag for API and CDMO businesses.
→No significant increase in debt is expected to support this capex.
→No new greenfield facilities are expected to start operations in FY26; expansion is mostly through existing sites.
→INR5,000 crores capex announcement includes backward integration and de-risking the supply chain to reduce dependence on China.
→Plans for ADC (Antibody-Drug Conjugate) segment include a $15 million investment focusing on conjugation (not mAbs).
→Animal Health and Crop Sciences CDMO are commercializing; expect significant revenue jump in FY26 with one more year needed to nurture crop sciences business.

How does Laurus Labs Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Laurus Labs Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Laurus Labs Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio